KR870700607A - 메발로노락톤의 이미다졸 유도체를 제조하는 방법 - Google Patents

메발로노락톤의 이미다졸 유도체를 제조하는 방법

Info

Publication number
KR870700607A
KR870700607A KR1019870700051A KR870700051A KR870700607A KR 870700607 A KR870700607 A KR 870700607A KR 1019870700051 A KR1019870700051 A KR 1019870700051A KR 870700051 A KR870700051 A KR 870700051A KR 870700607 A KR870700607 A KR 870700607A
Authority
KR
South Korea
Prior art keywords
alkyl
hydrogen
compound
formula
butyl
Prior art date
Application number
KR1019870700051A
Other languages
English (en)
Other versions
KR910003428B1 (ko
Inventor
제임스 리차드 웨어링
Original Assignee
산도즈 파마슈티칼스 코포레이션
예안 크래머
산도즈 리미티드
한즈 루돌프 하우즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 산도즈 파마슈티칼스 코포레이션, 예안 크래머, 산도즈 리미티드, 한즈 루돌프 하우즈 filed Critical 산도즈 파마슈티칼스 코포레이션
Publication of KR870700607A publication Critical patent/KR870700607A/ko
Application granted granted Critical
Publication of KR910003428B1 publication Critical patent/KR910003428B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/02—Optical fibres with cladding with or without a coating
    • G02B6/02033—Core or cladding made from organic material, e.g. polymeric material
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/44—Mechanical structures for providing tensile strength and external protection for fibres, e.g. optical transmission cables
    • G02B6/4401—Optical cables
    • G02B6/4429—Means specially adapted for strengthening or protecting the cables
    • G02B6/443—Protective covering
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/44—Mechanical structures for providing tensile strength and external protection for fibres, e.g. optical transmission cables
    • G02B6/4401—Optical cables
    • G02B6/4429—Means specially adapted for strengthening or protecting the cables
    • G02B6/4436—Heat resistant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/05—Filamentary, e.g. strands
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2913—Rod, strand, filament or fiber
    • Y10T428/2933—Coated or with bond, impregnation or core
    • Y10T428/2938—Coating on discrete and individual rods, strands or filaments
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2913—Rod, strand, filament or fiber
    • Y10T428/2933—Coated or with bond, impregnation or core
    • Y10T428/2962—Silane, silicone or siloxane in coating
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2913—Rod, strand, filament or fiber
    • Y10T428/2933—Coated or with bond, impregnation or core
    • Y10T428/2964—Artificial fiber or filament
    • Y10T428/2967—Synthetic resin or polymer

Abstract

내용 없음

Description

메발로노락톤의 이미다졸 유도체를 제조하는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. a) X가 -(CH2)m- 또는 (E)-CH=CH-이고, R17은 어느 것이거나 R18이며, Z가 일반식(a)의 그룹이고, 여기에서 R13은 수소이며, R14가 R16(이는 C1-3알킬, n-부틸, i-부틸, t-부틸 또는 벤질이다)일 경우, 일반식(XVII)의 화합물을 환원시키거나, b) X가 -(CH2)m- 또는 (E)-CH=CH-이고, Z가 일반식(a)의 그룹이며, 여기에서 R13은 R13a이고, R17은 각각 독립적으로 R18또는 M2 일 경우, 일반식 (IXa)의 화합물을 가수분해시키거나, c) R17이 R18이고, R13이 수소이며, X가 -CH=CH- 또는 -CH2-CH=CH-이고, Z가 4R, 6S 배열을 나타내는 일반식(b)의 그룹이거나, X가 -CH2CH2- 또는 -CH2CH2CH2-이며, Z가 4R, 6R 배열을 나타내는 일반식(b)의 그룹일 경우, 일반식(Va)의 화합물을 탈실릴화시키거나, d) R17이 R18이고, X가 -CH2CH2-, -CH2CH2CH2-, -CH=CH-, -CH=CH-CH2- 또는 -CH2-CH=CH-이며, Z가 일반식(a)의 그룹(여기에서 R14는 R16이다)일 경우, 일반식(XI)의 화합물을 탈실릴화시키거나, e) Z가 일반식(c)의 그룹이고, 여기에서 Q가이며, R14가 R16이고 R17은 어느 것이거나 R18이며, X가 X7일 경우, Q가[즉, Z가 일반식(a)의 그룹이다]인 상응하는 일반식(I)의 화합물을 산화시키거나, f) Z가 에스테르 형태의 일반식(c)의 그룹이며, 여기에서 Q가이고, R17는 어느 것이거나 R18이며, X가 X7일 경우, Q가인 상응하는 일반식(I)의 화합물을 케탈화시키거나, g) 에스테르 또는 락톤 형태의 일반식(I)의 화합물을 가수분해시키거나, h) 유리산 형태의 일반식(I)의 화합물을 에스테르화 또는 락톤화 시키고, 유리카복실 그룹이 생성될 경우, 유리산 형태 또는 염의 형태로 수득된 화합물을 회수시킴을 특징으로 하여 일반식(I)의 화합물 또는 그의 약제학적으로 허용되는 산부가염을 제조하는 방법.
    상기 식에서, R1은 비대칭 탄소원자를 함유하지 않는 C1-6알킬, C3-7사이클로알킬, 아다만틸-1 또는(여기에서 R4, R5및 R6는 후술하는 바와 같다)이며, R2는 비대칭 탄소원자를 함유하지 않는 C1-6알킬, C3-7사이클로알킬, 아다만틸-1 또는(여기에서 R7, R8및 R9는 후술하는 바와 같다)이고, R3는 수소, 비대칭탄소 원자를 함유하지 않는 C1-6알킬, C3-7사이클로알킬, 아다만틸-1, 스티릴 또는(여기에서 R10, R11및 R12는 후술하는 바와 같다)이며, X는 -(CH2)m-, -CH-, -CH=CH-CH-CH2= 또는 -CH2-CH=CH-이고, 여기에서 m은 0, 1, 2 또는 3이며, Z는이고, 여기에서 Q는또는이며, 여기에서 R15는 각각 비대칭 탄소원자를 함유하지 않는 1급 또는 2급 C1-6알킬이고, 두 R15는 동일하거나, 두 R15는 함께 -(CH2)q-(여기에서 q는 2 또는 3이다)이며, R13는 수소 또는 C1-3알킬이고, R14는 수소, R16(이는 생리학적으로 허용되는 에스테르 그룹이다) 또는 M(이는 양이온이다)이며; 단, Z는 (i) X가 -CH=CH- 또는 -CH2-CH=CH-이거나, (ii) R13가 C1-3알킬이거나 (iii) (i) 및 (ii)일 경우에만은 일반식(c)의 그룹이어야 하고; R4, R7및 R10은 각각 독립적으로 수소, C1-3알킬, n-부틸, i-부틸, t-부틸, C1-3알콕시, n-부톡시, i-부톡시, 트리플루오로메틸, 플루오로, 클로로, 브로모, 페닐, 페녹시 또는 벤질옥시이며, R5, R8및 R11은 각각 독립적으로 수소, C1-3알킬, C1-3알콕시, 트리플루오로메틸, 플루오로, 클로로, 브로모, -COOR17, -N(R19)2, 페녹시 또는 벤질옥시이고, 여기에서 R17은 수소, R18(이는 C1-3알킬, n-부틸, i-부틸, t-부틸 또는 벤질이다) 또는 M(M은 상기 정의한 바와 같다)이며, R19은 각각 독립적으로 비대칭 탄소원자를 함유하지 않는 C1-6알킬이고, R6, R9및 R12은 각각 독립적으로 수소, C1-2알킬, C1-2알콕시, 플루오로 또는 클로로이며; 단, 환 A, B 및 C의 각각에 있어서 하나 이하의 치환체가 독립적으로 트리플루오로메틸, 페녹시 및 벤질옥시이어야 하고, X8은 (i) -CH=CH- 또는 CH2CH=CH-이거나 (ii) -CH2CH2- 또는 -CH2CH2CH2-이며, X9은 (i) -CH2CH2- 또는 -CH2CH2CH2-이거나, (ii) -CH=CH-, -CH=CH-CH2- 또는 -CH2-CH=CH-이고, ImA는 R17이 각각 독립적으로 R18일 경우 일반식의 그룹(여기에서 R1, R2및 R3는 상기 정의한 바와 같다)이며, R'16는 C1-3알킬, n-부틸, i-부틸, t-부틸 또는 벤질이고, R13a는 C1-3알킬이며, M2 는 나트륨 또는 칼륨이고, R22는 C1-3알킬이며; 단, (1) Z가일 경우에, 화합물은 유리염기 형태이며, (i) R14가 R16이고, R17이 각각 독립적으로 R18이거나, (ii) R14가 M이며 R17이 각각 독립적으로 R18또는 M이고, (2) (i) R14또는 하나이상의 R17이 M이거나, (ii) R14및 하나 이상의 R17이 M일 경우, 화합물은 유리산 형태이어야 한다.
  2. 제1항에 있어서, M이 각각 독립적으로 약제학적으로 허용되는 양이온인 방법.
  3. 제2항에 있어서, a) R1이 비대칭 탄소원자를 함유하지 않는 C1-6알킬, C3-7사이클로알킬 또는 아다민틸-1이고, R2가인 화합물, b) Z가a)의 화합물, c) R1이 비대칭 탄소원자를 함유하지 않는 C1-6알킬이며, R3가 비대칭 탄소원자를 함유하지 않는 C1-6알킬, 사이클로헥실 또는이고, R7이 수소, C1-3알킬, 플루오로, 클로로 또는 브로모이며, R8이 수소, C1-2알킬, 플루오로 또는 클로로이고, R9이 수소, 또는 메틸이며, R13이 수소 또는 메틸이고, R14이 수소, C1-3알킬, n-부틸, i-부틸, t-부틸, 벤질 또는 M이며, X가 -CH2CH2- 또는 -CH=CH-인 b)의 화합물, d) R1이 C1-3알킬, n-부틸 또는 i-부틸이고, R3가이며, R13가 수소이고, R14가 수소, C1-3알킬 또는 M이며, X가 (E)-CH=CH-인 c)의 화합물, e) R10이 수소, C1-3알킬, C1-2알콕시, 트리플루오로메틸, 플루오로, 클로로, 브로모 또는 페닐이고, R11이 수소, C1-2알킬, 플루오로, 클로로, 브로모, -COOR'17(여기에서 R'17는 수소, C1-3알킬 또는 M이다) 또는 -N(R'19)2(여기에서 R'19는 각각 독립적으로 C1-2알킬이다)이며, R12는 수소 또는 메틸이고, R14는 수소, C1-2알킬 또는 M인 d)의 화합물, f) R1이 C1-3알킬이고, R7이 수소, 메틸 또는 플루오로이며, R8이 수소 또는 메틸이고, R10이 수소, 메틸 또는 플루오로이며, R11이 수소 또는 메틸인 일반식 e)의 화합물,
    g) R9이 수소이고, R12가 수소인 f)의 화합물, h) R14가 약제학적으로 허용되는 양이온인 g)의 화합물, i) 일반식의 그룹의 3- 및 5-위치에 있는 하이드록시 그룹이 에리트로 배열을 나타내는 h)의 화합물, j) Z가인 a)의 화합물,k) Z가인 a)의 화합물, l) R1이 이고, R2가 비대칭 탄소원자를 함유하지 않는 C1-6알킬, C3-7사이클로알킬 또는 아다만틸-1인 화합물, m) Z가인 l)의 화합물, n) R1이이고, R2가인 화합물, o) R1이 비대칭 탄소원자를 함유하지 않는 C1-6알킬 C3-7사이클로 알킬 또는 아다만틸-1이고, R2가 비대칭 탄소원자를 함유하지 않는 C1-6알킬, C3-7사이클로 알킬 또는 아다만틸-1인 화합물로 이루어진 그룹중에서 선택되는 화합물을 제조하는 방법.
  4. 제1항에 있어서, 다음 a) 내지 l)로 이루어진 그룹중에서 선택되는 화합물을 제조하는 방법.
    상기 식에서 M은 약제학적으로 허용되는 양이온이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870700051A 1985-05-22 1986-05-16 메발로노락톡의 이미다졸 유도체를 제조하는 방법 KR910003428B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/736,679 US4668794A (en) 1985-05-22 1985-05-22 Intermediate imidazole acrolein analogs
US736679 1985-05-22
PCT/EP1986/000297 WO1986007054A1 (en) 1985-05-22 1986-05-16 Imidazole analogs of mevalonolactone and derivatives thereof

Publications (2)

Publication Number Publication Date
KR870700607A true KR870700607A (ko) 1987-12-30
KR910003428B1 KR910003428B1 (ko) 1991-05-31

Family

ID=24960855

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870700051A KR910003428B1 (ko) 1985-05-22 1986-05-16 메발로노락톡의 이미다졸 유도체를 제조하는 방법

Country Status (18)

Country Link
US (1) US4668794A (ko)
EP (1) EP0235164B1 (ko)
JP (1) JPS62502894A (ko)
KR (1) KR910003428B1 (ko)
AU (1) AU594064B2 (ko)
DE (1) DE3673003D1 (ko)
DK (1) DK33287A (ko)
ES (1) ES8707191A1 (ko)
FI (1) FI865162A (ko)
GR (1) GR861319B (ko)
HU (1) HUT41743A (ko)
IL (1) IL78858A (ko)
NZ (1) NZ216234A (ko)
PH (1) PH25768A (ko)
PL (1) PL149929B1 (ko)
PT (1) PT82623B (ko)
WO (1) WO1986007054A1 (ko)
ZA (1) ZA863840B (ko)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0244364A3 (en) * 1986-04-30 1992-04-01 Sandoz Ag Preparation of olefinic compounds
IL83821A0 (en) * 1986-09-10 1988-02-29 Sandoz Ag Azaindole and indolizine derivatives,their production and pharmaceutical compositions containing them
US4898949A (en) * 1987-02-25 1990-02-06 Bristol-Myers Company Intermediates for the preparation of antihypercholesterolemic tetrazole compounds
US4897490A (en) * 1987-02-25 1990-01-30 Bristol-Meyers Company Antihypercholesterolemic tetrazole compounds
US5300252A (en) * 1987-03-13 1994-04-05 Fmc Corporation Ether free organometallic amide compositions
US5091378A (en) * 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
US4761419A (en) * 1987-12-07 1988-08-02 Warner-Lambert Company 6-(((substituted)quinolinyl)ethyl)-and ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
NO890522L (no) * 1988-02-25 1989-08-28 Bayer Ag Substituerte imidazolinoner og imidazolinthioner.
IT1226726B (it) * 1988-07-29 1991-02-05 Zambon Spa Composti attivi come inibitori della biosintesi del colesterolo.
US5196440A (en) * 1988-07-29 1993-03-23 Zambon Group S.P.A. Compounds active as inhibitors of the cholesterol biosynthesis
US5010205A (en) * 1988-08-23 1991-04-23 Bristol-Myers Company Antihypercholesterolemic tetrazol-1-yl intermediates
US4870187A (en) * 1988-08-23 1989-09-26 Bristol-Myers Company Antihypercholesterolemic tetrazol-1-yl compounds
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
AU628862B2 (en) * 1988-10-03 1992-09-24 Glaxo Group Limited Substituted n-vinyl imidazole derivatives
MY105067A (en) * 1988-10-13 1994-07-30 Novartis Ag Process for the preparation of 7-substituted-hept-6-enoic and -heptanoic acids and derivatives and intermediates thereof.
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
DK0955294T3 (da) * 1989-06-14 2004-02-02 Smithkline Beecham Corp Imidazolylalkensyre
US5418250A (en) * 1989-06-14 1995-05-23 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5106992A (en) * 1989-07-28 1992-04-21 E. R. Squibb & Sons, Inc. 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US4970221A (en) * 1989-07-28 1990-11-13 E. R. Squibb & Sons, Inc. 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
EP0422895A1 (en) * 1989-10-10 1991-04-17 Glaxo Group Limited Chemical compounds
US5177096A (en) * 1989-10-25 1993-01-05 Smithkline Beecham Corporation Substituted 5-((tetrazolyl)alkenyl)imidazoles and pharmaceutical methods of use thereof
IT1237793B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
IT1237792B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
US5011851A (en) * 1990-02-13 1991-04-30 Bristol-Myers Squibb Co. Imidazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
CA2036192A1 (en) 1990-02-13 1991-08-14 Nicholas Meanwell Heterocyclic carboxylic acids and esters
US5049578A (en) * 1990-03-09 1991-09-17 E. R. Squibb & Sons, Inc. 1-aroyl or 1-acyl-2-2pyrrolidinyl-3,5-dihydroxy alkanoic and alkenoic acids, salts, esters and lactones
US5728842A (en) * 1992-06-30 1998-03-17 Smithkline Beecham Corporation Substituted imidazolyl-alkylthio-alkanoic acids
GB9213934D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Chemical compounds
FR2696746B1 (fr) * 1992-10-12 1994-11-18 Synthelabo Dérivés de l'acide benzèneborinique, leur préparation et leur utilisation comme intermédiaires de synthèse.
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP2004536047A (ja) 2001-04-11 2004-12-02 ブリストル−マイヤーズ　スクイブ　カンパニー 糖尿病処置用ｃ−アリールグルコシドのアミノ酸複合体および方法
NZ531788A (en) 2001-10-18 2008-01-31 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
AU2003225305A1 (en) 2002-05-08 2003-11-11 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
WO2003103632A1 (en) 2002-06-10 2003-12-18 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
AU2003282983A1 (en) 2002-10-23 2004-05-13 Bristol-Myers Squibb Company Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
MXPA05005813A (es) 2002-12-20 2005-12-12 Pfizer Prod Inc Formas de dosificacion que comprenden un inhibidor de la cetp y un inhibidor de la hmg-coa reductasa.
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
EP1625861A4 (en) 2003-05-21 2012-04-11 Jms Co Ltd CONTAINER FOR SERUM PRODUCTION AND REGENERATIVE MEDICINE METHOD USING SAID CONTAINER
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
CA2532207A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
BRPI0416639A (pt) 2003-11-19 2007-01-16 Metabasis Therapeutics Inc tiromiméticos contendo fósforo
KR20060129082A (ko) 2004-03-05 2006-12-14 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과연관된 질환 또는 질병의 치료 방법
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
US20050252144A1 (en) * 2004-04-29 2005-11-17 Macdonald Robert A Veneers for walls, retaining walls and the like
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7220859B2 (en) 2005-01-12 2007-05-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076597A1 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
WO2006087630A2 (en) * 2005-02-16 2006-08-24 Warner-Lambert Company Llc OXYPYRAZOLE HMG Co-A REDUCTASE INHIBITORS
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
US20070042034A1 (en) * 2005-07-22 2007-02-22 Myriad Genetics, Incorporated High drug load formulations and dosage forms
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
EP1943215A2 (en) 2005-10-31 2008-07-16 Brystol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
EP2089355A2 (en) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
EP2581081A3 (en) 2007-06-01 2013-07-31 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
CN101808995A (zh) 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
JP5465177B2 (ja) 2007-09-20 2014-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物
WO2009073564A1 (en) * 2007-11-29 2009-06-11 The Hospital For Sick Children Compositions and methods for treating lysosomal disorders
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
JP2012522015A (ja) 2009-03-27 2012-09-20 ブリストル−マイヤーズ スクイブ カンパニー Ｄｐｐ−ｉｖ阻害剤を用いて主要有害心血管事象を予防する方法
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
BR112012008004A2 (pt) 2009-10-09 2016-03-29 Irm Llc compostos e composições como moduladores da atividade de gpr119
US8871264B2 (en) 2009-11-13 2014-10-28 Astrazeneca Ab Immediate release tablet formulations
RU2583920C2 (ru) 2009-11-13 2016-05-10 Астразенека Аб Композиция двухслойной таблетки
CA2780938A1 (en) 2009-11-13 2011-05-19 Bristol-Myers Squibb Company Reduced mass metformin formulations
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
CN102971313A (zh) 2010-04-14 2013-03-13 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
EP2590634B1 (en) 2010-07-09 2016-03-09 BHV Pharma, Inc. Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
PL2925735T3 (pl) 2012-11-20 2019-08-30 Lexicon Pharmaceuticals, Inc. Inhibitory kotransportera sodowo-glukozowego 1
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
WO2016176656A2 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
EA202190226A1 (ru) 2018-07-19 2021-06-16 Астразенека Аб СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
BR112021004839A2 (pt) 2018-09-26 2021-06-08 Lexicon Pharmaceuticals, Inc. formas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-triidróxi-6-(metiltio)tetraidro-2h-piran-2-il)benzil)fenil)butanamida e métodos de sua síntese

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (ko) * 1974-06-07 1981-03-18
JPS53147073A (en) * 1977-05-24 1978-12-21 Sankyo Co Ltd Mevalonolactone derivatives
JPS5559180A (en) * 1978-10-30 1980-05-02 Sankyo Co Ltd 4-hydroxy-2-pyrone ring compound, its preparation, and remedy for hyperlipemia comprising it as active constituent
JPS5559140A (en) * 1978-10-30 1980-05-02 Sankyo Co Ltd 3,5-dihydroxypentanoic alkyl ester derivative, its preparation and remedy for hyperlipemia containing the same as the effective component
JPS567775A (en) * 1979-06-29 1981-01-27 Sankyo Co Ltd 4-alkoxy-2-pyrrone derivative
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4351844A (en) * 1980-02-04 1982-09-28 Merck & Co., Inc. Hypocholesterolemic hydrogenation products and process of preparation
PT72801B (en) * 1980-04-14 1983-01-10 Merck & Co Inc Process for synthesis of substituted biphenyl-2-carboxaldehydes
JPS56150037A (en) * 1980-04-22 1981-11-20 Sankyo Co Ltd Hydronaphthalene compound
US4308378A (en) * 1980-09-02 1981-12-29 Merck & Co., Inc. Cis/trans isomerization of 6-(substituted-aryl-ethenyl)-3,4,5,6-tetrahydro-4-hydroxy-2H-pyran-2-ones
US4440927A (en) * 1981-06-19 1984-04-03 Merck & Co., Inc. Process for preparing inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase via a chiral synthon
EP0068038B1 (en) * 1981-06-29 1985-09-25 Merck & Co. Inc. (+)-(4r,6s)-(e)-6-(2-(4'-fluoro-3,3',5-trimethyl-(1,1'-biphenyl)-2-yl)ethenyl)-3,4,5,6-tetrahydro-4-hydroxy-2h-pyran-2-one, a process for preparing and a pharmaceutical composition containing the same
US4376863A (en) * 1981-08-21 1983-03-15 Merck & Co., Inc. Hypocholesterolemic fermentation products
US4387242A (en) * 1981-08-21 1983-06-07 Merck & Co., Inc. Hypocholesterolemic fermentation products and process of preparation
AU9133682A (en) * 1981-12-23 1983-06-30 Akira Endo Dihydro- and tetrahydromonacolin l- and their salts and esters
US4474971A (en) * 1982-09-29 1984-10-02 Sandoz, Inc. (Tetrahydropyran-2-yl)-aldehydes
HU204253B (en) * 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
US4503072A (en) * 1982-12-22 1985-03-05 Merck & Co., Inc. Antihypercholesterolemic compounds
ATE23326T1 (de) * 1983-01-24 1986-11-15 Sandoz Ag Mevalonslakton-analoge und ihre derivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zusammensetzungen sowie deren verwendung als heilmittel.
US4530922A (en) * 1984-01-03 1985-07-23 E. I. Du Pont De Nemours And Company Fungicidal imidazoles and triazoles containing silicon
DE3582674D1 (de) * 1984-06-22 1991-05-29 Sandoz Ag Pyrazolanaloge von mevalonolakton und abkoemmlinge davon, verfahren zu deren herstellung und deren verwendung.

Also Published As

Publication number Publication date
IL78858A (en) 1991-03-10
PT82623A (en) 1986-06-01
EP0235164A1 (en) 1987-09-09
DK33287D0 (da) 1987-01-21
KR910003428B1 (ko) 1991-05-31
PL149929B1 (en) 1990-04-30
FI865162A0 (fi) 1986-12-17
PT82623B (pt) 1988-08-17
GR861319B (en) 1986-09-19
PH25768A (en) 1991-10-18
NZ216234A (en) 1990-01-29
JPS62502894A (ja) 1987-11-19
DE3673003D1 (de) 1990-08-30
ES555199A0 (es) 1987-07-16
ES8707191A1 (es) 1987-07-16
FI865162A (fi) 1986-12-17
AU594064B2 (en) 1990-03-01
EP0235164B1 (en) 1990-07-25
WO1986007054A1 (en) 1986-12-04
HUT41743A (en) 1987-05-28
IL78858A0 (en) 1986-09-30
US4668794A (en) 1987-05-26
DK33287A (da) 1987-01-21
AU5960686A (en) 1986-12-24
ZA863840B (en) 1987-12-30

Similar Documents

Publication Publication Date Title
KR870700607A (ko) 메발로노락톤의 이미다졸 유도체를 제조하는 방법
KR840001156A (ko) 벤지미다졸 유도체의 제조방법
KR870700063A (ko) 메발로노락톤의 인덴유도체 및 이들의 유도체
IE822836L (en) Method of preparing benzothiazepine derivatives
ES8505650A1 (es) Un metodo de producir una emulsion grasa que contiene ester alquilico de prostaglandina e1
KR840007221A (ko) 메발로락톤 및 그 유도체의 제조 방법
AU560643B2 (en) P-oxybenzoic acid derivatives
ES477784A1 (es) Procedimiento para la preparacion de nuevas 2-fenilimino-imidazolidinas sustituidas.
JPS5549352A (en) Cyclic iminocarboxylic acid derivative and its salt
KR860001045A (ko) 메발로노락톤의 나프틸 동족체의 제조방법
IE810232L (en) Phenyl hydroxyalkyl ethers and thioethers
GB1496491A (en) Dihydroergopeptine derivatives
DE3070768D1 (en) 1-((substituted-naphthyl)ethyl)-imidazole derivatives, pharmaceutical compositions containing them and methods of making them
EP0112451A3 (en) Prostaglandin and hydroxylated fatty acid ester formulations
KR840006334A (ko) 설파모일 벤조페논 유도체의 제조방법
JPS56145946A (en) Stabilized polyurethane composition
JPS5287173A (en) 4-(pyridyl-2-oxy)phynoxyalkanecarboxylic acid compounds
GB1513916A (en) Stable ophthalmic formulation
JPS54161332A (en) Photographic photosensitive sheet for color diffusion transfer
JPS5649307A (en) Oil-in-water type suspension insecticidal and acaricidal composition
CH609682A5 (en) Process for the preparation of compounds analogous to prostaglandins
GB2001974A (en) Vincinic acid derivatives and process for the preparation thereof
IE44999L (en) Hydrazinopyridazine derivatives.
ES8400121A1 (es) Procedimiento para la obtencion de derivados de 11-amino-papulacandina a y b.
DE3175939D1 (en) Use of gamma-piperidino-butyrophenones for the preparation of medicaments for treating diarrhoea

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee